-
Nanomaterials for cancer nanomedicine: Case studiesWhitepaperCancer nanomedicine has emerged as a highly promising approach for improving the effectiveness and safety of cancer therapy. Nanoparticles have been engineered to selectively target cancer cells, overcome biological barriers, and deliver a wide range of therapeutic payloads including small molecules, nucleic acids, and proteins.
-
Infographic: Adapting Lateral Flow Assays for Nucleic Acid DetectionInfographicLateral flow assays are well-known for their ability to rapidly detect the presence or absence of proteins. Although easy to perform, its widespread adoption for other applications has been limited due to several constraints.
-
White Paper: Quality Considerations for a Successful Diagnostic Assay LaunchWhitepaperThe increase in infectious disease prevalence has led to a heightened demand for in-vitro diagnostics that have low complexity, are portable, rapid, and inexpensive to manufacture. Lateral flow assays (LFAs) have addressed this demand in the recent past during the Covid-19 pandemic.
-
5 Reasons for Selecting Antibodies and Antigens from Fortis for Your Lateral Flow AssayInfographicReliable quality reagents are fundamental to the performance of a lateral flow assay. In addition to high sensitivity and specificity, it is recommended that antibodies used in lateral flow assays are tested for use in this format since they typically perform differently in lateral flow vs other formats such as ELISA or western blot.
-
White Paper: Considerations for Developing Saliva-based Lateral Flow ImmunoassaysWhitepaperLateral flow assays (LFAs) designed for diagnostic applications at home (over-the-counter, OTC) and point-of-care (PoC) are simple to use and can test for a wide variety of biomarkers in a diverse set of matrices including saliva, nasal swabs, blood, and urine.
